Diaceutics (LSE:DXRX) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:DXRX Diaceutics PLC LSE:DXRX
88 GF Score
Price £1.70
GF Value £2.00
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Diaceutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diaceutics  (LSE:DXRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Diaceutics Cyclically Adjusted PS Ratio Related Terms


Diaceutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Diaceutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics Cyclically Adjusted PS Ratio Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 5.16

Diaceutics Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 5.16

LSE:DXRX vs VEEV, BTSG, TEM: Cyclically Adjusted PS Ratio Comparison

For the Health Information Services subindustry, Diaceutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diaceutics Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Diaceutics's Cyclically Adjusted PS Ratio falls into.


LSE:DXRX
88GF Score
Diaceutics PLC LSE:DXRX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diaceutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Diaceutics's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Diaceutics's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.452/139.9000*139.9000
=0.452

Current CPI (Dec25) = 139.9000.

Diaceutics Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.044 102.200 0.060
201712 0.106 105.000 0.141
201812 0.149 107.100 0.195
201912 0.209 108.500 0.269
202012 0.163 109.400 0.208
202112 0.164 114.700 0.200
202212 0.227 125.300 0.253
202312 0.281 130.500 0.301
202412 0.381 135.100 0.395
202512 0.452 139.900 0.452

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Diaceutics (LSE:DXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of £1.70 is trading 15% below its estimated GF Value™ of £2.00. GuruFocus considers Diaceutics to be Modestly Undervalued.

Key valuation signals for LSE:DXRX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: £2.00 vs. price of £1.70 (15% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the LSE:DXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diaceutics Business Description

Other Exchanges DIUXF:USA7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
88GF Score

Get the complete analysis for LSE:DXRX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.70
Price
£2.00
GF Value